Full Year Report 2003 Quarterly Report October-December 2003
FULL YEAR REPORT 2003 QUARTERLY REPORT OCTOBER-DECEMBER 2003 · A preclinical milestone for a second compound was reached and a milestone payment was received in May in the Merck & Co., Inc. collaboration. · In August Merck & Co., Inc. decided to discontinue the development of the first drug candidate selected in 2002. · Karo Bio obtained all rights to compounds and technologies, including the A-348441 lead compound, in the collaboration with Abbott Laboratories in November. Karo Bio has selected the A-348441 compound from the Abbott collaboration as a candidate drug for type 2 diabetes. · A